gelteq.com (GELS): חובות להיוון בספרים

Gelteq Limited management is focusing on drug validation, which correlates with the debt-to-equity ratio on the GURU.Markets terminal linear chart, where the current parameter is 0.34. The business relies on gel delivery patents and strict FDA control. Prospects depend on the success of licensing deals and the results of clinical trials.

The resilience assessment of Gelteq Limited is based on an analysis of the debt-to-equity ratio. This debt-to-equity structure chart reflects the extent to which the company's assets cover its liabilities. This metric determines financial leverage and the risk of default in the absence of operating profit. For GELS, this balance is critical, as development depends on costly clinical trials and licensing deals. Low leverage here ensures survival until the commercialization of gel technologies.